Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Application of ProteinChip array profiling in serum biomarker discovery for patients suffering from severe acute respiratory syndrome.
PMID 18220240 · PMC7120874 · Methods in molecular biology (Clifton, N.J.) · 2007 · 8 claims · 5 setups
SELDI-TOF-MS ProteinChip array profiling of serum can identify differentially expressed protein biomarkers in SARS-CoV infected patients versus controls.
-
Full-text index only
Serum diagnosis of diffuse large B-cell lymphomas and further identification of response to therapy using SELDI-TOF-MS and tree analysis patterning.
PMID 18163913 · PMC2242801 · BMC cancer · 2007 · 8 claims · 8 setups
SELDI-TOF-MS serum proteomic patterns analyzed by decision tree classification (Biomarker Pattern Software) can discriminate DLBCL patients from healthy controls with high sensitivity and specificity.
-
Full-text index only
[Research progress in SELDI-TOF MS and its clinical applications].
PMID 17168305 · PMC7148935 · Sheng wu gong cheng xue bao = Chinese journal of biotechnology · 2006 · 4 claims · 4 setups
Proteinchip profiling based on SELDI-TOF MS is a powerful and innovative proteomic technology for biomarker discovery and diagnostic/prognostic assay development.
-
Full-text index only
Diagnostic proteomics: serum proteomic patterns for the detection of early stage cancers.
PMID 15258335 · PMC3851082 · Disease markers · 2003 · 8 claims · 8 setups
Proteomic pattern analysis of serum mass spectra, without identifying the underlying proteins, can distinguish cancer patients from healthy controls with high sensitivity and specificity.
-
Full-text index only
Biomarker discovery in neurodegenerative diseases: a proteomic approach.
PMID 18938247 · PMC2939006 · Neurobiology of disease · 2009 · 6 claims · 8 setups
Proteomic profiling of CSF and plasma can identify candidate protein biomarkers that distinguish AD patients from controls with high sensitivity and specificity
-
Full-text index only
Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer.
PMID 19689818 · PMC2743709 · BMC cancer · 2009 · 7 claims · 3 setups
The previously reported classifier (m/z 8,132 and 4,002) failed to discriminate CRC patients from healthy volunteers in this independent validation cohort
-
Full-text index only
SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.
PMID 18644101 · PMC2481502 · Breast cancer research : BCR · 2008 · 7 claims · 3 setups
SELDI-TOF MS proteomic profiling of breast carcinomas identifies patient subgroups with differential co-expression of protein peaks that are analogous to gene-expression-based classifications (luminal, basal, HER2 subtypes)
-
Full-text index only
Discovery and identification of potential biomarkers of papillary thyroid carcinoma.
PMID 19785722 · PMC2761863 · Molecular cancer · 2009 · 8 claims · 7 setups
A 3-peak (m/z 9190, 6631, 8697 Da) SVM classification model discriminates PTC from non-cancer controls with high sensitivity and specificity
-
Full-text index only
Urinary proteomic profiling for diagnostic bladder cancer biomarkers.
PMID 19811072 · PMC3422861 · Expert review of proteomics · 2009 · 8 claims · 8 setups
Single protein biomarkers (e.g., NMP-22, BTA) suffer from high false-positive rates and none have replaced cystoscopy or cytology for bladder cancer detection.